GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement covers development and commercialization of linerixibat as GSK reallocates ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to trial ...

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...